JACC VOL. 71, NO.

19, 2018 Corrections 2275

MAY 15, 2018:2272–80

16. On page 2259, in Appendix 1, for Dr. Ovbiagele, column 4, “Speakers Bureau,” read, “None.” It has been
updated to read, “Boehringer Ingelheim Korea Ltd.”
17. On page 2260, in Appendix 1, for Dr. Wright, column 4, “Speakers Bureau,” read, “None.” It has been
updated to read, “Amgeny*”.
18. On page 2260, in the Appendix 1 footnotes, the first paragraph previously read:
This table represents the relationships of committee members with industry and other entities (RWI)
that are considered relevant to this document. Although most ACC/AHA guideline writing committees
are constituted such that no more than half the members may have relevant RWI for 1 year before and
during development of the guideline, rules for the prevention guidelines require that no members have
relevant RWI from 1 year before appointment until 1 year after publication of the guideline. Members’
RWI were reviewed and updated at all meetings and conference calls of the writing committee during
the document development period. The complete ACC/AHA policy on RWI is available at http://www.
acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy.

It has been updated with 2 new paragraphs to read:

This table represents the relationships of committee members with industry and other entities that were
determined to be relevant to this document. These relationships were reviewed and updated in
conjunction with all meetings and/or conference calls of the writing committee during the document
development process. The table does not necessarily reflect relationships with industry at the time of
publication. A person is deemed to have a significant interest in a business if the interest represents
ownership of $5% of the voting stock or share of the business entity, or ownership of $$5000 of the fair
market value of the business entity; or if funds received by the person from the business entity exceed 5%
of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also
included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.
According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates
to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the
document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or
device addressed in the document, or makes a competing drug or device addressed in the document; or c)
the person or a member of the person’s household, has a reasonable potential for financial, professional or
other personal gain or loss as a result of the issues/content addressed in the document. The complete ACC/
AHA policy on RWI is available at http://www.acc.org/guidelines/about-guidelines-and-clinical-
documents/relationships-with-industry-policy.

19. On page 2260, in the Appendix 1 footnotes, “ySignificant relationship.” has been added.

These corrections have been made to the current online version of the article, which is available at
https://doi.org/10.1016/j.jacc.2017.11.005.
Ó 2018 American College of Cardiology.
https://doi.org/10.1016/j.jacc.2018.03.017

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S,
Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS,
Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr.

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/
PCNA Guideline for the Prevention, Detection, Evaluation, and
Management of High Blood Pressure in Adults: A Report of the
American College of Cardiology/American Heart Association Task
Force on Clinical Practice Guidelines
J Am Coll Cardiol 2018;71:e127–248.

1. On page e127, in the author list, “FACC” has been removed after Dr. Gidding’s name.
2. On page e129, the 9.5. heading read, “9.5. Peripheral Arterial Disease.” It has been updated to read, “9.5.
Peripheral Artery Disease.” It has also been updated on page e208 in Table 22 and on page e209 in Table 23.
2276 Corrections JACC VOL. 71, NO. 19, 2018
MAY 15, 2018:2272–80

3. On page e137, in the footnote for Table 5, first paragraph, last sentence, the reference 12 citation has been
removed from the end of the sentence.
4. On page e144, Figure 1 has been amended as follows:
 The third box from the left (“Masked Hypertension”) was labeled as Class IIb. It has been updated to
Class IIa. The shading of the box has also been updated.
 The fourth box from the left (“Elevated BP”) was labeled as Class IIb. It has been updated to Class IIa.
The shading of the box has also been updated.
5. On page e145, Figure 2, bottom row, the second box from the left read, “Continue current therapy (Class
IIa).” It has been updated to read, “Continue current therapy”; the Class of Recommendation color has
been removed.
6. On page e152, in Table 14, the text in the first column, last row read, “Angiogenesis inhibitor (e.g.,
bevacizumab) and tyrosine kinase inhibitors (e.g., sunitinib, sorafenif).” It has been updated to read,
“Angiogenesis inhibitor (e.g., bevacizumab) and tyrosine kinase inhibitors (e.g., sunitinib, sorafenib).”
7. On page e155, section “6.2. Nonpharmacological Interventions,” under “Synopsis,” first paragraph, the
first sentence read, “Nonpharmacological interventions.sodium reduction (8–11), potassium
supplementation, increased physical activity (18–20,22,31), and ..” It has been updated to read,
“Nonpharmacological interventions.sodium reduction (S6.2-8—S6.2-12), potassium supplementation
(S6.2-13,S6.2-17), increased physical activity (S6.2-18—S6.2-22,S6.2-31), and..”
8. On page e155, section “6.2. Nonpharmacological Interventions,” under “Synopsis,” first paragraph, the
third sentence read, “Such interventions include.low-carbohydrate and vegetarian diets (5,7,46–49),
(18–20,22,23,31,50).” It has been updated to read, “Such interventions include.low-carbohydrate,
vegetarian, and Mediterranean diets (S6.2-46—S6.2-49).”
9. On page e155, section “6.2. Nonpharmacological Interventions,” under “Synopsis,” the last paragraph,
which read, “Table 15 is a summary of best proven nonpharmacological interventions for prevention and
treatment of hypertension.” has been deleted.
10. On page e157, section “6.2. Nonpharmacological Interventions,” under “Recommendation-Specific Sup-
portive Text,” third paragraph, the third sentence read, “Lifestyle change. on the DASH diet (5) or
following a weight loss intervention (12).” It has been updated to read, “Lifestyle change. on the DASH
diet (S6.2-5) or receiving a weight loss intervention (S6.2-12).”
11. On page e158, section “6.2. Nonpharmacological Interventions,” under “Recommendation-Specific Sup-
portive Text,” fourth paragraph, the last sentence read, “This can be achieved by a diet.high in potassium
content (6).” It has been updated to read, “This can be achieved by a diet.high in potassium content
(S6.2-7).”
12. On page e162, legend to Figure 4, the second sentence, read, “*Using the ACC/AHA Pooled Cohort Equations
(57).” It has been updated to read, “*Using the ACC/AHA Pooled Cohort Equations (S8.1.2-56,S8.1.2-57).”
13. On page e161, section “8.1.2. BP Treatment Threshold and the Use of CVD Risk Estimation to Guide Drug
Treatment of Hypertension,” under “Synopsis,” second paragraph, the third from the last sentence read,
“It should be kept in mind.adults ages 45 to 79 years..” It has been updated to read, “It should be kept in
mind.adults ages 40 to 79 years..”
14. On page e163, the section “8.1.3. Follow-Up After Initial BP Evaluation” recommendation table title read,
“Recommendations for Follow-Up After Initial BP Elevation.” It has been updated to read, “Recommen-
dations for Follow-Up After Initial BP Evaluation.”
15. On pages e165 and e166, in “Table 18. Oral Antihypertensive Drugs”, the following changes have been made:
 In the “Primary agents” section, the first row “Thiazide or thiazide-type Diuretics,” the “Metolazone”
section, the “Usual Dose, Range (mg/d)*”column read, “2.5–10.” It has been updated to read, “2.5–5.”
 In the “Primary agents” section, the second row “ACE inhibitors,” the “Ramipril” section, the “Usual
Dose, Range (mg/d)*”column read, “2.5–10.” It has been updated to read, “2.5–20.”
 In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Felodipine” section, the
“Usual Dose, Range (mg/d)*”column read, “5–10.” It has been updated to read, “2.5–10.”
 In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nicardipine SR” section,
the “Usual Dose, Range (mg/d)*”column read, “5–20.” It has been updated to read, “60–120.” The “Daily
Frequency column read, “1.” It has been updated to read, “2.”
 In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nifedipine LA” section,
the “Usual Dose, Range (mg/d)*”column read, “60–120.” It has been updated to read, “30–90.”
JACC VOL. 71, NO. 19, 2018 Corrections 2277
MAY 15, 2018:2272–80

 In the “Primary agents” section, the fourth row “CCB—dihydropyridines,” the “Nisoldipine” section, the
“Usual Dose, Range (mg/d)*”column read, “30–90.” It has been updated to read, “17–34.”
 In the “Primary agents” section, the fifth row “CCB—nondihydropyridines, the “Diltiazem SR” section
has been removed.
 In the “Primary agents” section, the fifth row “CCB—nondihydropyridines, the “Diltiazem ER” section,
the “Usual Dose, Range (mg/d)*”column read, “120–480.” It has been updated to read, “120–360.”
 In the “Primary agents” section, the fifth row “CCB—nondihydropyridines, the “Verapamil IR” section,
the “Usual Dose, Range (mg/d)*”column read, “40–80.” It has been updated to read, “120–360.”
 In the “Primary agents” section, the fifth row “CCB—nondihydropyridines, the “Verapamil SR” section,
the “Usual Dose, Range (mg/d)*”column read, “120–480.” It has been updated to read, “120–360.”
 In the “Primary agents” section, the fifth row “CCB—nondihydropyridines, the “Verapamil-delayed
onset ER” section, the “Drug” column read, “Verapamil-delayed onset ER (various forms).” It has been
updated to read, “Verapamil-delayed onset ER.”
 In the “Primary agents” section, the fifth row “CCB—nondihydropyridines, the “Verapamil-delayed
onset ER” section, the “Usual Dose, Range (mg/d)*”column read, “100–480.” It has been updated to
read, “100–300.”
 In the “Secondary agents” section, the first row “Diuretics—loop,” the “Bumetanide” section, the “Usual
Dose, Range (mg/d)*”column read, “0.5–4.” It has been updated to read, “0.5–2.”
 In the “Secondary agents” section, the first row “Diuretics—aldosterone antagonists,” the “Eplerenone”
section, the “Daily Frequency” column read, “12.” It has been updated to read, “1 or 2.”
 In the “Secondary agents” section, the second row “Beta blockers—cardioselective,” the “Atenolol”
section, the “Daily Frequency” column read, “12.” It has been updated to read, “2.”
 In the “Secondary agents” section, the second row “Beta blockers—cardioselective,” the “Metoprolol
tartrate” section, the “Usual Dose, Range (mg/d)*”column read, “100–400.” It has been updated to read,
“100–200.”
 In the “Secondary agents” section, the fourth row “Beta blockers—noncardioselective,” the “Propranolol
IR” section, the “Usual Dose, Range (mg/d)*”column read, “160–480.” It has been updated to read,
“80–160.”
 In the “Secondary agents” section, the fourth row “Beta blockers—noncardioselective,” the “Propranolol
LA” section, the “Usual Dose, Range (mg/d)*”column read, “80–320.” It has been updated to read,
“80–160.”
 In the “Secondary agents” section, the fifth row “Beta blockers—intrinsic sympathomimetic activity,”
the “Carteolol” section is deleted.
 In the “Secondary agents” section, the eighth row “Alpha-1 blockers,” the “Doxazosin” section, the
“Usual Dose, Range (mg/d)*”column read, “1–8.” It has been updated to read, “1–16.”
 In the “Secondary agents” section, the penultimate row, the “Class” column read, “Central alpha1 -
agonist and other centrally acting drugs.” It has been updated to read, “Central alpha 2-agonist and other
centrally acting drugs.”
 In the “Secondary agents” section, the last row “Direct vasodilators,” the “Hydralazine” section, the
“Usual Dose, Range (mg/d)*”column read, “250–200.” It has been updated to read, “100–200.”
16. On page e168, in section “8.1.6. Choice of Initial Medication” under “Synopsis,” first paragraph, the second
sentence read, “When initiation of pharmacological. are indicated (see Section 9) (1,3).” It has been
updated to read, “When initiation of pharmacological. are indicated (see Section 9) (S8.1.6-1).”
17. On page e168, in section “8.1.6. Choice of Initial Medication” under “Synopsis,” first paragraph, the third
sentence read, “In the largest head-to-head comparison of first-step drug therapy for hypertension (4,5),
the..” It has been updated to read, “In the largest head-to-head comparison of first-step drug therapy for
hypertension (S8.1.6-3), the..”
18. On page e168, in section “8.1.6. Choice of Initial Medication” under “Synopsis,” first paragraph, the fifth
sentence read, “For black patients, ACE inhibitors were also notably less effective than CCBs in preventing
HF (5,10) and in the prevention of stroke (11,12)..” It has been updated to read, “For black patients, ACE
inhibitors were also notably less effective than CCBs in preventing HF (8.1.6-8) and in the prevention of
stroke (S8.1.6-9)..”
19. On page e224, in the references for section “8.1.6. Choice of Initial Medication,” 3 references have been
deleted:
2278 Corrections JACC VOL. 71, NO. 19, 2018
MAY 15, 2018:2272–80

Peart S. Results of MRC (UK) trial of drug therapy for mild hypertension. Clin Invest Med. 1987;10:616–20.
Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE)
trial: outcomes in patients receiving monotherapy. Hypertension. 2006;48:385–91.
Zanchetti A, Julius S, Kjeldsen S, et al. Outcomes in subgroups of hypertensive patients treated
with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial.
J Hypertens. 2006;24:2163–8.
20. On page e183, Figure 9, fifth row, the box underneath “Restart antihypertensive treatment (Class I)”
previously read, “Aim for BP <140/90 mm Hg (Class IIb).” It has been updated to read, “Aim for BP
<130/80 mm Hg (Class IIb).”
21. On page e193, in section “10.3.2. Children and Adolescents,” the last sentence read, “Publication of new
evidence-based pediatric guidelines is anticipated in late 2017.” It has been updated to read, “A new
pediatric BP guideline was published in late 2017 (S10.3.2-7).” A new reference has been added to the
section: Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and man-
agement of high blood pressure in children and adolescents. Pediatrics. 2017;140:e20171904.
22. On page e198, in section “11.4. Sexual Dysfunction and Hypertension,“ the second sentence read,
“Although these data converge to suggest that endothelial dysfunction is a common denominator, the
story is complete.” It has been updated to read, “Although these data converge to suggest that endothelial
dysfunction is a common denominator, the story is incomplete.”
23. On page e200, in section “11.5. Patients Undergoing Surgical Procedures,” under “Recommendation-Spe-
cific Supportive Text,” the third sentence in the second paragraph read, “Special consideration of place-
ment on parenteral therapy usually occurs for patients..” It has been updated to read, “Special
consideration of parenteral therapy usually occurs for patients..”
24. On page e209, Table 23, in the “Specific comorbidities” section, the seventh row “Secondary stroke pre-
vention (lacunar)” has been deleted.
25. On page e210, in the “Presidents and Staff” section for the American Heart Association, Ms. Hundley’s title
has been updated to read, “Manager, Production and Operations.”
26. On page e223, in the References for section “8.1.2. BP Treatment Threshold and the Use of CVD Risk
Estimation to Guide Drug Treatment of Hypertension,” the following reference has been added: “S8.1.2-56.
Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular
risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol. 2014;63:2935–59.” The following reference has been renumbered as “S8.1.2-
57”: “14. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood
cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol.
2014;63:2889–934.”
27. On page e224, in the references for section “8.1.5. BP Goal for Patients With Hypertension,” reference 16
read, “Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver
transplantation with tacrolimus (FK506) and cyclosporine. Transplantation. 1996;62:1588–92.” It has been
updated to read, “SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the
SPS3 randomised trial. Lancet. 2013;382:507–15.”
28. On page e238, in Appendix 1, for Dr. Carey, column 2 “Employment” read, “University of Virginia—Dean
Emeritus and University Professor, Department of Medicine.” It has been updated to read, “University of
Virginia School of Medicine—Dean, Emeritus, and Professor of Medicine.” Column 6, “Personal Research”
read, “None.” It has been updated to read, “Daiichi Sankyo, Inc.y”
29. On page e238, in Appendix 1, for Dr. Ovbiagele, column 4, “Speakers Bureau,” read, “None.” It has been
updated to read, “Boehringer Ingelheim Korea Ltd.”
30. On page e239, in Appendix 1, for Dr. Wright, column 4, “Speakers Bureau,” read, “None.” It has been
updated to read, “Amgeny*”.
31. On page e238 and page e239, in the Appendix 1 footnotes, the first paragraph previously read:
This table represents the relationships of committee members with industry and other entities (RWI)
that are considered relevant to this document. Although most ACC/AHA guideline writing committees
are constituted such that no more than half the members may have relevant RWI for 1 year before and
during development of the guideline, rules for the prevention guidelines require that no members have
JACC VOL. 71, NO. 19, 2018 Corrections 2279
MAY 15, 2018:2272–80

relevant RWI from 1 year before appointment until 1 year after publication of the guideline. Members’
RWI were reviewed and updated at all meetings and conference calls of the writing committee during
the document development period. The complete ACC/AHA policy on RWI is available at http://www.
acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy.

It has been updated with 2 new paragraphs to read:

This table represents the relationships of committee members with industry and other entities that were
determined to be relevant to this document. These relationships were reviewed and updated in
conjunction with all meetings and/or conference calls of the writing committee during the document
development process. The table does not necessarily reflect relationships with industry at the time of
publication. A person is deemed to have a significant interest in a business if the interest represents
ownership of $5% of the voting stock or share of the business entity, or ownership of $$5000 of the fair
market value of the business entity; or if funds received by the person from the business entity exceed
5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit
are also included for the purpose of transparency. Relationships in this table are modest unless other-
wise noted.
According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest
relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in
the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class,
or device addressed in the document, or makes a competing drug or device addressed in the document;
or c) the person or a member of the person’s household, has a reasonable potential for financial,
professional or other personal gain or loss as a result of the issues/content addressed in the document.
32. On page e239, in the Appendix 1 footnotes, “ySignificant relationship.” has been added.

These corrections have been made to the current online version of the article, which is available at
https://doi.org/10.1016/j.jacc.2017.11.006.
Ó 2018 American College of Cardiology Foundation, Inc.

https://doi.org/10.1016/j.jacc.2018.03.016

Patel MR, Calhoon JH, Dehmer GJ, Grantham JA, Maddox TM, Maron DJ, Smith PK

ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use

Criteria for Coronary Revascularization in Patients With Stable
Ischemic Heart Disease: A Report of the American College of
Cardiology Appropriate Use Criteria Task Force, American Association
for Thoracic Surgery, American Heart Association, American Society of
Echocardiography, American Society of Nuclear Cardiology, Society for
Cardiovascular Angiography and Interventions, Society of Cardiovascular
Computed Tomography, and Society of Thoracic Surgeons
J Am Coll Cardiol 2017;69:2212–41.
To more clearly reflect the relationship between iFR (instantaneous wave-free ratio) and FFR (fractional flow
reserve), the following changes were made to the document after its initial publication.

1. Page 2218, the following sentence has been added to the end of the final paragraph of Section 2. “Methods”:
“Other physiologic measurements using the ratio of distal coronary to aortic pressure without hyperemia
exist, and correlate with FFR, but are not as well-validated and lack the clinical outcomes data existing for
FFR.”
2. Page 2218, Section 3. “Assumptions”, “General Assumptions”. Assumption 1 previously comprised the
following sentence: “When available, each clinical scenario includes the patient’s clinical status/symptom
complex, ischemic burden as determined by noninvasive functional testing, burden of coronary athero-
sclerosis as determined by angiography, and additional invasive testing evaluations by invasive physiology
(e.g., FFR, instantaneous wave-free ratio) or intravascular imaging.” The parenthetical text in that sentence